Alyeska Investment Group
INAB icon

Alyeska Investment Group’s IN8bio INAB Stock Holding History

Alyeska Investment Group’s Portfolio INAB Stock Details INAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-27,322
Closed -$1.13M – 535
2023
Q4 		$1.13M Buy
+27,322
New +$873K 0.01% 404

Other funds holding INAB

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return

Alyeska Investment Group's INAB Position: Q2 2026 in Review

Alyeska Investment Group held its IN8bio (INAB) position steady in Q2 2026 at 944,319 shares worth $1.33M. The position accounts for ﹤0.01% of the portfolio, ranked #593.

Alyeska Investment Group first reported a position in INAB in Q4 2023 and has held it in 11 quarters since. The position peaked at $2.23M in Q4 2025. 21 funds tracked by Wall St. Rank hold INAB as of Q2 2026.

  • Alyeska Investment Group held 944,319 shares of IN8bio worth $1.33M as of Q2 2026.
  • Alyeska Investment Group left its IN8bio share count unchanged in Q2 2026.
  • IN8bio made up ﹤0.01% of Alyeska Investment Group's portfolio in Q2 2026, its #593 holding.
  • Alyeska Investment Group first reported a position in IN8bio in Q4 2023 and has held it in 11 quarters since.
  • Alyeska Investment Group's IN8bio position peaked at $2.23M in Q4 2025.
  • 21 funds tracked by Wall St. Rank held IN8bio as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.